Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06337084




Registration number
NCT06337084
Ethics application status
Date submitted
22/03/2024
Date registered
29/03/2024
Date last updated
22/05/2025

Titles & IDs
Public title
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Scientific title
Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Secondary ID [1] 0 0
MNPR-101-D001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor, Adult 0 0
Bladder Cancer 0 0
Urothelial Carcinoma 0 0
Triple-negative Breast Cancer 0 0
Lung Cancer 0 0
Colorectal Cancer 0 0
Gastric Cancer 0 0
Ovarian Cancer 0 0
Pancreatic Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MNPR-101-DFO*-89Zr
Diagnosis / Prognosis - PET/CT Diagnostic Imaging

Experimental: MNPR-101-DFO*-89Zr Single Infusion and PET/CT Imaging - Participants receive a single injection of MNPR-101-DFO\*-89Zr on Day 1 with administered activity between 37-74 MBq (or 1-2 mCi). PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10.


Treatment: Drugs: MNPR-101-DFO*-89Zr
Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans

Diagnosis / Prognosis: PET/CT Diagnostic Imaging
PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Diagnosis / Prognosis
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr
Timepoint [1] 0 0
Post infusion at 2 h on Day 1, once on Days 3-5, and once on Days 7-10.
Primary outcome [2] 0 0
To assess tumor Standard Uptake Value (SUV) of MNPR-101-DFO*-89Zr
Timepoint [2] 0 0
Post infusion at 2 h on Day 1, once on Days 3-5, and once on Days 7-10.
Primary outcome [3] 0 0
To assess safety of MNPR-101-DFO*-89Zr as assessed by CTCAE 5.0
Timepoint [3] 0 0
Screening through Day 30 Safety Visit.
Secondary outcome [1] 0 0
To assess pharmacokinetics (PK) of MNPR-101-DFO*-89Zr via well or gamma counter
Timepoint [1] 0 0
Post infusion at 10 min, 1 h and 2 h on Day 1, once on Days 3-5, and once on Days 7-10.

Eligibility
Key inclusion criteria
1. Histologically and/or cytologically confirmed solid tumor cancer.
2. Age =18 years.
3. Measurable disease = 1 cm on prior 18F-FDG PET/CT scan. Up to 4 subjects may be enrolled with FDG-avid disease which do not meet = 1 cm measurement on CT.
4. Ability to understand and willingness to sign a written informed consent document.
5. A prior standard-of-care 18F-FDG PET/CT scan within past 60 days.
6. Tumor sample available for IHC testing to demonstrate uPAR expression.
7. Females of childbearing potential must have a negative serum pregnancy test at time of screening and a negative urine pregnancy test on Day 1 prior to study drug administration if screening is >7 days prior to Day 1. A rapid serum pregnancy test result performed as standard-of-care will be accepted if available.
8. Both males and females must agree to use highly effective contraceptive precautions if conception is possible during the dosing period and up to 1 month after dosing.
9. Female patients who are lactating must agree to discontinue breastfeeding prior to the dose of study drug and must refrain from breastfeeding for 1 month following the last dose of study drug.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), or immunotherapy within 14 days prior to administration of MNPR-101-DFO*-89Zr, or continuing adverse effects (>grade 1, excluding alopecia, anorexia, fatigue, and neuropathy) from such therapy (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0).
2. Prior treatment with any radiopharmaceutical or investigational agents within 4 weeks or 5 effective half-lives, whichever is longer, prior to administration of the first dose of MNPR-101-DFO*-89Zr.
3. Have evidence of impaired organ function at Screening and within 1 week prior to dosing MNPR-101-DFO*-89Zr, particularly:

* Bone marrow i. Platelets <75 K/mcL. ii. ANC <1.0 K/mcL.
* Liver function i. AST/ALT >2.5xULN (institutional upper limits of normal) OR >5×ULN for patients with liver metastases.

ii. Bilirubin >1.5xULN OR >3×ULN for patients with known Gilbert's Syndrome.
* Renal function i. eGFR =45 mL/min determined using BSA-adjusted Chronic Kidney Disease Epidemiology Collaboration CKD-EPI 2021 formula [https://www.kidney.org/professionals/kdoqi/gfr_calculator].
4. Other serious, non-malignant diseases that may interfere (e.g., renal, hepatic, or hematologic) with the objectives of the study, safety, or compliance, as judged by the investigator.
5. Cognitive impairment or contraindications that may compromise the ability to give informed consent or comply with the requirements of the study.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/05/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2026
Actual
Sample size
Target
12
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Melbourne Theranostic Innovation Centre (MTIC) - North Melbourne
Recruitment postcode(s) [1] 0 0
3051 - North Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Monopar Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Prof. Rod Hicks, MD
Address 0 0
Melbourne Theranostic Innovation Centre (MTIC)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Director Clinical Operations
Address 0 0
Country 0 0
Phone 0 0
847-794-8435
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06337084